Edesa Biotech to Unveil Phase 3 AKI Mortality Reduction Data at ERA Congress
EDSA•Edesa Biotech will present exploratory Phase 3 data on paridiprubart at the European Renal Association Congress June 3–6, showcasing a statistically significant reduction in mortality among acute kidney injury patients with respiratory distress. The company reports over 400 patients treated across studies and plans additional analysis to bolster paridiprubart’s first-in-class anti-TLR4 mechanism for a condition without approved targeted therapies.
1. Presentation Details
Edesa Biotech’s oral presentation, titled "Exploratory Analysis of Paridiprubart, an Anti-TLR4 Antibody, in Patients with Acute Kidney Injury and Respiratory Distress," is scheduled for June 5, 2026 at 4:30 pm local time during the 63rd European Renal Association Congress in Glasgow. The session will feature peer-reviewed exploratory data alongside additional analyses planned for release on the company’s website.
2. Phase 3 Data Highlights
The Phase 3 study of paridiprubart demonstrated a consistent, statistically significant reduction in mortality among AKI patients experiencing respiratory distress—an acute complication with high short-term fatality and no approved targeted therapies. More than 400 subjects have received the antibody in clinical trials to date, with results indicating a favorable safety profile and robust anti-inflammatory effects.
3. Paridiprubart and Market Context
Paridiprubart is a first-in-class monoclonal antibody targeting Toll-like Receptor 4 to modulate hyperinflammation in conditions such as ARDS, sepsis and acute kidney injury. AKI affects an estimated 13 million people annually worldwide, driving prolonged hospital stays and elevated mortality, yet current management remains supportive; Edesa aims to fill this unmet need with its host-directed therapy.
